Epix Initiates Second Trial in Phase IIb Alzheimer's Disease Study
Posted on: Thursday, 12 June 2008, 12:00 CDT
US based Epix Pharmaceuticals has initiated a second trial in its Phase IIb program in Alzheimer's disease.
The Phase IIb proof-of-concept program consists of two clinical trials - a six-month trial evaluating PRX-03140 in combination with donepezil that began earlier this month and this three-month trial studying PRX-03140 as monotherapy. PRX-03140 is part of Epix's strategic collaboration with GlaxoSmithKline.
This randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy of PRX-03140 on cognitive function as measured by the change from baseline in the cognitive component of the Alzheimer's disease assessment scale (ADAS-Cog) score.
The ADAS-Cog endpoint is the current standard for evaluating drug efficacy for cognition in Alzheimer's disease and is an established and accepted regulatory endpoint. Patients will be randomized to one of four trial arms: placebo, donepezil positive control, 50mg/daily of PRX-03140, or 150mg/daily of PRX-03140.
The three month trial is expected to enroll approximately 240 adult patients with Alzheimer's disease that are either intolerant to acetylcholinesterase inhibitors or are newly diagnosed. This monotherapy trial will also include a three month optional extension that will have the ADAS-cog as the primary endpoint.
Source: Datamonitor
Related Articles
- EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient
- Prana Announces Success in Phase IIa Clinical Trial of PBT2 in Early Alzheimer's Disease
- EPIX Pharmaceuticals Announces Updated Results From Phase 2a Clinical Trial of PRX-03140 in Alzheimer's Disease
- EPIX Pharmaceuticals Reports Compelling Clinical Results for PRX-03140 in Alzheimer's Disease; Statistically Significant Improvement in Cognitive Function Achieved Within Two Weeks
- Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
- EPIX Pharmaceuticals Initiates Phase 2a Clinical Trial in Patients With Mild Alzheimer's Disease
- Predix Pharmaceuticals Announces Findings From Preclinical Cognition Studies at the 10th International Conference on Alzheimer's Disease; PRX-03140 is Expected to Enter into a Phase II Clinical Trial Later This Year
- Thousands of Cambodia's Cows Hit By Foot-and-Month Disease
- Predix Pharmaceuticals Initiates Phase Ib Clinical Trials of 5-HT4 Agonist for Alzheimer's Disease and Other Cognitive Disorders
- Myriad Genetics Initiates Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
 |
 |
User Comments (0)
RSS Feeds